INTRODUCTION AND OBJECTIVES: Resection of residual masses (>1cm) after chemotherapy is recommended in patients with testicular non-seminomatous germ cell tumor (NSGCT). Traditionally, resections in the abdomen and chest are performed as separate surgical procedures. The aim of this study was to compare a simultaneous versus a sequential approach to residual mass resections.
METHODS: A retrospective review was performed of all patients who underwent both retroperitoneal and thoracic resection of post chemotherapy residual masses at the Princess Margaret Cancer Centre between 2002 and 2018. Patients were divided into two groups: Group 1-Simultaneous (Combined Retroperitoneal and Thoracic resections at the same sitting) Group 2: Sequential (Retroperitoneal and Thoracic resections at separate dates).
RESULTS: During the study period, 35 simultaneous and 17 sequential resections were performed. The mean age of patient at surgery was 28 years (Range 16-61). The mean follow up from final surgery was 48.3 months (Range 1-239). Histology revealed teratoma in 38 (73.1%) patients, necrosis in 8 (15.4%) and viable tumor in 6 (11.5%). Discordant pathology findings between thoracic and abdominal resections were noted in 16 (30.8%) patients.
There was no difference in overall mean length of operating time (mins) between the two groups (635 mins vs 405 mins þ 218 mins, p[0.77). There was no difference in overall blood loss (mls) between the two groups (1904 mls vs 2258mls þ 301mls, p[0.39). There was no difference in overall mean length of stay (days) between the two groups (14.8 days vs 9.5 days þ 8.2days, p[0.72).
Patients who underwent sequential surgeries had a longer time from consent to completion of completion of surgery (8.4 months vs 2.1 months, p[0.0001).
Overall, there was a recurrence rate of 30.8% (n[16). Two patients have died of testicular cancer.
CONCLUSIONS: Simultaneous resection of retroperitoneal and thoracic post chemotherapy metastases is a feasible and safe approach. It does entail multidisciplinary co-operation and a longer primary procedure.
Source of Funding: None.
MP73-11 PENILE SQUAMOUS CELL CARCINOMA IS GENOMICALLY SIMILAR TO OTHER HPV-DRIVEN TUMORS

INTRODUCTION AND OBJECTIVES: Penile Squamous Cell
Carcinoma (PSCC) is rare with limited treatment options for advanced disease. There have been no published genome-wide studies on the genetic alterations of PSCCs or on the differences between human papillomavirus (HPV) positive and HPV negative PSCCs. We report the largest whole exome sequencing (WES) analysis of PSCC.
METHODS: We identified 34 pts diagnosed with PSCC at the University of Texas MD Anderson Cancer Center with primary tumors or metastatic lesions sufficient for WES. Patients, tumor, and surgical characteristics were available through the MD Anderson prospective registry. Genomic DNAs from both Fresh frozen macrodissected tumors and paired-normal penile tissues were analyzed by WES.
RESULTS: Patient's clinical characteristics are summarized in table 1. Eight of the most frequently mutated PSCC genes (NOTCH1 (35%), TP53 (35%), CDKN2A (24%), PIK3CA (21%), CASP8 (21%), FAT1 (18%), FBXW7 (15%) and EP300 (12%)) were significantly mutated in other SCC tumor types. Importantly, 8/8 and 5/8 genes were significant in head and neck SCC and cervical SCC, respectively, including 3 (CASP8, FXBW7, and EP300) genes that are only significant in these tumor types. TP53 mutations were associated with HPV negative PSCC and were absent in HPV positive SCC (P[ 0.03). EP300 mutations were associated with advanced primary tumor stage. Of note, we did not identify unique mutations associated with lymph node status.
CONCLUSIONS: This is the largest systematic analyses of PSCC genomics uncovering the involvement of multiple cancer genes that are likely to be contributing to tumor development including TP53, squamous differentiation, cell cycle, and chromatin regulation. PSCCs are genomically similar to other HPV related SCC, and provide a therapeutic rationale for considering strategies successful in HPV related cancers.
